Advertisement
Advertisement
ALGS
Aligos Therapeutics, Inc. Common Stock
5.59
USDSponsored
+0.08
+1.45%
Aug 07, 15:59 UTC -4
Closed
After-Market
5.72
+0.13
+2.34%
ALGS Earnings Reports
Positive Surprise Ratio
ALGS beat 13 of 24 last estimates.
54%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$816.00K
/-$2.26
Implied change from Q2 26 (Revenue/ EPS)
-97.06%
/+1514.29%
Implied change from Q3 25 (Revenue/ EPS)
+10.12%
/-25.66%
Aligos Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, ALGS reported earnings of -0.14 USD per share (EPS) for Q2 26, beating the estimate of -1.09 USD, resulting in a 87.21% surprise. Revenue reached 27.78 million, compared to an expected 18.61 million, with a 49.29% difference. The market reacted with a +16.24% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -2.26 USD, with revenue projected to reach 816.00 thousand USD, implying an increase of 1514.29% EPS, and decrease of -97.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Aligos Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Aligos Therapeutics, Inc. Common Stock reported EPS of -$0.14, beating estimates by 87.21%, and revenue of $27.78M, 49.29% above expectations.
How did the market react to Aligos Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 16.24%, changed from $4.74 before the earnings release to $5.51 the day after.
When is Aligos Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Aligos Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Aligos Therapeutics, Inc. Common Stock is expected to report EPS of -$2.26 and revenue of $816.00K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement